Beta Blockers After Heart Attack

Do beta blockers still help after an uncomplicated heart attack?

Beta blockers became a cornerstone of post-myocardial infarction care decades ago, when blocked arteries were less often reopened quickly and the risk of fatal rhythm disturbances was higher. Modern heart attack treatment now usually includes rapid coronary revascularization, antiplatelet therapy, high-intensity statins, blood pressure control, and cardiac rehabilitation, which changes the baseline risk that beta blockers were originally meant to reduce.

The REBOOT trial tested this older standard in a contemporary setting. Researchers enrolled 8,505 patients from 109 hospitals in Spain and Italy after myocardial infarction without reduced ejection fraction, then randomized them to beta-blocker therapy or no beta blocker on top of standard care. Over a median follow-up of almost four years, beta blockers did not significantly lower the combined risk of death, recurrent myocardial infarction, or hospitalization for heart failure.

Which patients may still benefit from beta blockers?

The new findings should not be read as a rejection of beta blockers for all cardiovascular disease. These medicines still have established roles in heart failure with reduced ejection fraction, certain rhythm disorders, angina, and selected blood pressure scenarios. The key distinction is whether a patient has a specific reason to need beta blockade after the acute heart attack period.

Other recent evidence adds nuance. The REDUCE-AMI trial, published in the New England Journal of Medicine in 2024, also found no apparent reduction in death or recurrent myocardial infarction among patients with acute myocardial infarction and preserved ejection fraction. At the same time, pooled analyses suggest patients with mildly reduced function, often defined around 40% to 49% ejection fraction, may be different from patients whose function is fully normal.

What should patients taking beta blockers do now?

For patients already taking metoprolol, bisoprolol, carvedilol, atenolol, or another beta blocker, the practical message is review, not sudden discontinuation. Stopping beta blockers abruptly can worsen chest pain, heart rhythm symptoms, or blood pressure control in some people, particularly when the medicine is being used for angina, arrhythmia, or heart failure.

The REBOOT sex-specific analysis also raised a caution signal in women with fully preserved heart function, reporting higher risk among women treated with beta blockers compared with those not treated, while the same signal was not observed in men. Subgroup findings require careful interpretation, but they reinforce the larger clinical point: post-heart-attack medication lists should be reassessed against current evidence, symptoms, ejection fraction, and competing risks rather than continued automatically.